Comparison of ATTRACT and CaVenT
| . | ATTRACT . | CaVenT* . | ||
|---|---|---|---|---|
| CDT . | Control . | CDT . | Control . | |
| Patients, n | 336 | 355 | 87 | 89 |
| Age, y† | 52 | 53 | 58 | 53 |
| Male, n (%) | 205 (61) | 221 (62) | 57 (66) | 53 (60) |
| Major bleeds, n (%)‡ | 19 (5.7) | 13 (3.7) | 3 (2.7) | 0 (0) |
| Nonmajor bleeds, n (%)‡ | 46 (14) | 38 (11) | 5 (4.6) | 0 (0) |
| Final incidence of PTS, n (%)§ | 77 (31) | 85 (36) | 37 (42.5) | 63 (70.8) |
| Severe PTS, n (%)§ | NR | NR | 4 (1) | 1 (1) |
| Final mean Villalta§ | 3.40 | 4.56 | NR | NR |
| . | ATTRACT . | CaVenT* . | ||
|---|---|---|---|---|
| CDT . | Control . | CDT . | Control . | |
| Patients, n | 336 | 355 | 87 | 89 |
| Age, y† | 52 | 53 | 58 | 53 |
| Male, n (%) | 205 (61) | 221 (62) | 57 (66) | 53 (60) |
| Major bleeds, n (%)‡ | 19 (5.7) | 13 (3.7) | 3 (2.7) | 0 (0) |
| Nonmajor bleeds, n (%)‡ | 46 (14) | 38 (11) | 5 (4.6) | 0 (0) |
| Final incidence of PTS, n (%)§ | 77 (31) | 85 (36) | 37 (42.5) | 63 (70.8) |
| Severe PTS, n (%)§ | NR | NR | 4 (1) | 1 (1) |
| Final mean Villalta§ | 3.40 | 4.56 | NR | NR |
NR, not reported.
5-year follow up from the CaVenT trial,4 which included fewer patients than the 2-year outcomes.5
Mean age was reported for CaVenT; median age was reported in ATTRACT.
Bleeding events: reported as all bleeding events from time of randomization to 1-year follow-up in the ATTRACT trial. The CaVenT trial reported bleeding events as bleeding events related to CDT over the course of 1 year following randomization. Nonmajor bleeds refers to clinically relevant nonmajor bleeding.
Outcomes reported at the conclusion of each trial rather than the cumulative incidence (2-year visit for ATTRACT; 5-year visit for CaVenT). The ATTRACT trial also reported the mean Villalta scores of patients at the final 2-year study visit.